Brief: Galapagos Says Total Operating Loss From Continuing Operations For Three Months Ended 31 March 2024 Was EUR 33.1 Million

Lakefront Biotherapeutics NV

02/05/2024 21:04

May 2 (Reuters) - Galapagos NV  GLPG.AS :
    * GALAPAGOS - TOTAL OPERATING LOSS FROM CONTINUING
OPERATIONS FOR
THREE MONTHS ENDED 31 MARCH 2024 WAS EUR 33.1 MILLION, COMPARED
TO EUR 14.2 MILLION
    * PLAN TO FILE INVESTIGATIONAL NEW DRUG APPLICATIONS IN U.S.
TO
PROGRESS CLINICAL DEVELOPMENT OF OUR CAR-T PROGRAMS IN
HEMATO-ONCOLOGY
    * FOR FULL YEAR 2024, WE RECONFIRM OUR CASH BURN GUIDANCE OF
EUR
280 MILLION TO EUR 320 MILLION

Source text for Eikon:  ID:nGNEGkYyP 
Further company coverage:  GLPG.AS 

 ((Reuters.Briefs@thomsonreuters.com;))